Trial Profile
Phase III Open-Label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder After Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Subjects Who Completed Participation in Study CTBM100C2303
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Jun 2021
Price :
$35
*
At a glance
- Drugs Tobramycin (Primary)
- Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
- Focus Adverse reactions
- Sponsors Novartis
- 02 Apr 2013 New trial record